Reimbursement / E-health
Mayzent ® is reimbursed in Belgium as from 1st November 2021.
* Detailed reimbursement criteria can be found at www.riziv.fgov.be in Dutch or...
Mayzent ® is reimbursed in Belgium as from 1st November 2021.
* Detailed reimbursement criteria can be found at www.riziv.fgov.be in Dutch or...
Anne de Pauw (North)
+32473330366
Sylvie...
In patients with a CYP2C9*3*3 genotype, MAYZENT ® should not be used.
*1mg tablet will be available in Q4 2022 in Belgium – Q1 2023 in Luxembourg Procedures to request reimbursement for the 1 mg tablets...
Reimbursement for 3 types of patients
Patients insufficiently responding despite a full and adequate course of treatment with at least one first line treatment...
Scemblix ® is indicated for the treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (Ph+ CML CP) previously treated with two or more tyrosine kinase inhibitors.
1....